Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 12/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.46 |
| ▸ | RAF1 | P04049 | 1/20 | 0.40 |
| ▸ | BRAF | P15056 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.37 |
| ▸ | FEN1 | P39748 | 1/20 | 0.37 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18285335 | 0.93 | P2RY14 (0.52) | P2RY14MCHR1RAF1BRAFRIPK1 | |
| SCHEMBL18285309 | 0.89 | P2RY14 (0.41) | P2RY14RIPK1ALOX5APFEN1 | |
| SCHEMBL18285304 | 0.87 | CNR1 (0.42) | P2RY14RIPK1KCNH2 | |
| SCHEMBL18285306 | 0.86 | P2RY14 (0.51) | P2RY14MCHR1RAF1BRAFRIPK1 | |
| SCHEMBL18706212 | 0.83 | P2RY14 (0.55) | P2RY14MCHR1OPRD1KCNH2 | |
| SCHEMBL20921663 | 0.83 | P2RY14 (0.43) | P2RY14MCHR1RAF1BRAFRIPK1 | |
| SCHEMBL18285343 | 0.82 | P2RY14 (0.40) | P2RY14RAF1BRAFRIPK1ALOX5AP | |
| SCHEMBL18389397 | 0.82 | P2RY14 (0.42) | P2RY14MCHR1RIPK1ALOX5APFEN1 | |
| SCHEMBL18172487 | 0.80 | P2RY14 (0.56) | P2RY14MCHR1OPRD1KCNH2 | |
| SCHEMBL18285370 | 0.80 | CNR1 (0.42) | P2RY14RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | claimed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | claimed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | claimed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | claimed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | claimed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | claimed |
| CN-107531642-B | Imidazole derivatives | 豪夫迈·罗氏有限公司 | 2021-06-22 | — | — | CN | disclosed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | disclosed |
| EP-3303299-B1 | IMIDAZOLE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2019-04-24 | — | — | EP | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-10029989-B2 | Imidazole derivatives | HOFFMANN-LA ROCHE INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2018-05-03 | — | — | US | disclosed |
| EP-3303299-A1 | IMIDAZOLE DERIVATIVES | H. Hoffnabb-La Roche Ag (CH) | 2018-04-11 | — | — | EP | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
| WO-2016193235-A1 | IMIDAZOLE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2016-12-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180118692-A1 | IMIDAZOLE DERIVATIVES | DRD3, GABRR3, DRD4 | P2RY14 3572/4885MCHR1 43/4885RAF1 810/4885 |
| US-10029989-B2 | Imidazole derivatives | DRD3, GABRR3, DRD4 | P2RY14 3572/4885MCHR1 43/4885RAF1 810/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.